BE
Beam Therapeutics
BEAM · NASDAQ
$24.23 +0.87% (+$0.21)
1M -17.67%
Market Cap $2.49B
P/E Ratio -
Div. Yield -
ROE 7.70%
Bulios Fair Price
$19.49
19.6% downside
Current Price
$24.23
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BEAM is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
40 /100
Fair P/S 15.98x
P/B 2.34x
P/E N/A
Growth
100 /100
Growing Rev. growth 31.88%
Book val. growth 19.07%
EPS growth N/A
Profitability
5 /100
Weak Gross margin 18.93%
FCF margin 238.90%
Net margin 54.75%
Quality
1 /100
Poor ROIC 28.62%
Asset turnover 0.11x
ROE 7.70%
Debt
69 /100
Low Debt/Equity 0.23x
Int. coverage -7.76x
Current ratio 14.57x
Stability
1 /100
Unstable Beta 2.23x
Profitable years 0
Rev. volatility 306.90%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BEAM
Online
Sector
Healthcare
Industry
Biotechnology
CEO
John Evans
Employees
540
Headquarters
Cambridge
Upcoming events
03 NOV
Earnings
Upcoming earnings report